Product Description
Esflurbiprofen is a topically applied, non-steroidal anti inflammatory drug (NSAID). It is the more active enantiomer of racemic flurbiprofen. (Sourced from: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9420)
Mechanisms of Action: COX Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Transdermal
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Japan | Malaysia | Philippines
Approved Indications: None
Known Adverse Events: None
Company: Teikoku
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Germany
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Acute Pain|Contusions
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
TK-254RX-0301 | P3 |
Unknown Status |
Acute Pain |
2025-08-31 |
|
TK-254RX-0302 | P3 |
Unknown Status |
Contusions |
2025-08-31 |